Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P23352
UPID:
KALM_HUMAN
Alternative names:
Adhesion molecule-like X-linked; Kallmann syndrome protein
Alternative UPACC:
P23352; B2RPF8
Background:
Anosmin-1, also known as Adhesion molecule-like X-linked or Kallmann syndrome protein, plays a crucial role in neural development. It is pivotal in the patterning of mitral and tufted cell collaterals to the olfactory cortex, serving as a chemoattractant for fetal olfactory epithelial cells.
Therapeutic significance:
Anosmin-1's dysfunction is linked to Hypogonadotropic hypogonadism 1 with or without anosmia, a condition marked by delayed sexual maturation and olfactory deficits. Understanding the role of Anosmin-1 could open doors to potential therapeutic strategies for treating this genetic disorder.